Results 11 to 20 of about 1,208 (158)

Inhibitory Effects of Fosmidomycin Against Babesia microti in vitro [PDF]

Frontiers in Cell and Developmental Biology, 2020
Babesia microti, the main pathogen causing human babesiosis, has been reported to exhibit resistance to the traditional treatment of azithromycin + atovaquone and clindamycin + quinine, suggesting the necessity of developing new drugs.
Sen Wang, Sen Wang, Muxiao Li, Muxiao Li, Xiaoying Luo, Xiaoying Luo, Long Yu, Long Yu, Zheng Nie, Zheng Nie, Qin Liu, Qin Liu, Xiaomeng An, Xiaomeng An, Yangsiqi Ao, Yangsiqi Ao, Qin Liu, Jiaxu Chen, Yu Tian, Junlong Zhao, Junlong Zhao, Junlong Zhao, Lan He, Lan He, Lan He   +24 more
doaj   +3 more sources

Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake [PDF]

BMC Microbiology, 2008
Fosmidomycin is a phosphonic antibiotic which inhibits 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr), the first committed step of the non-mevalonate pathway of isoprenoid biosynthesis.
Parish Tanya, Brown Amanda C
doaj   +3 more sources

Methyl-Jasmonate Functions as a Molecular Switch Promoting Cross-Talk between Pathways for the Biosynthesis of Isoprenoid Backbones Used to Modify Proteins in Plants [PDF]

Plants
In plants, the plastidial mevalonate (MVA)-independent pathway is required for the modification with geranylgeranyl groups of CaaL-motif proteins, which are substrates of protein geranylgeranyltransferase type-I (PGGT-I).
Quentin Chevalier, Alexandre Huchelmann, Pauline Debié, Pierre Mercier, Michael Hartmann, Catherine Vonthron-Sénécheau, Thomas J. Bach, Hubert Schaller, Andréa Hemmerlin   +8 more
doaj   +2 more sources

Beyond the MEP Pathway: A novel kinase required for prenol utilization by malaria parasites. [PDF]

PLoS Pathogens
A proposed treatment for malaria is a combination of fosmidomycin and clindamycin. Both compounds inhibit the methylerythritol 4-phosphate (MEP) pathway, the parasitic source of farnesyl and geranylgeranyl pyrophosphate (FPP and GGPP, respectively). Both
Marcell Crispim, Ignasi Bofill Verdaguer, Agustín Hernández, Thales Kronenberger, Àngel Fenollar, Lydia Fumiko Yamaguchi, María Pía Alberione, Miriam Ramirez, Sandra Souza de Oliveira, Alejandro Miguel Katzin, Luis Izquierdo   +10 more
doaj   +2 more sources

Synthesis and Antiplasmodial Activity of Novel Fosmidomycin Derivatives and Conjugates with Artemisinin and Aminochloroquinoline [PDF]

Molecules, 2020
Malaria, despite many efforts, remains among the most problematic infectious diseases worldwide, mainly due to the development of drug resistance by Plasmodium falciparum.
Despina Palla, Antonia I. Antoniou, Michel Baltas, Christophe Menendez, Philippe Grellier, Elisabeth Mouray, Constantinos M. Athanassopoulos   +6 more
doaj   +4 more sources

Fosmidomycin for the Treatment of Canine Otitis Externa: A Randomised, Double-Blinded, Controlled 'Split Body' Clinical Trial. [PDF]

Vet Dermatol
ABSTRACT Background Targeted antimicrobial therapy for canine otitis externa (OE) represents an opportunity for antimicrobial stewardship. Fosmidomycin selectively inhibits the non‐mevalonate pathway for isoprenoid biosynthesis utilised by canine‐adapted, and not human‐adapted, staphylococci.
Citron LE, Stefanovski D, You Y, Proctor R, Watson D, Randall J, Cain CL.   +6 more
europepmc   +2 more sources

Expanding the Chemical Space of Reverse Fosmidomycin Analogs. [PDF]

ACS Med Chem Lett
Multidrug-resistant pathogens pose a major threat to human health, necessitating the identification of new drug targets and lead compounds that are not susceptible to cross-resistance. This study demonstrates that novel reverse thia analogs of the phosphonohydroxamic acid antibiotic fosmidomycin inhibit 1-deoxy-d-xylulose 5-phosphate reductoisomerase ...
Knak T, Takada S, Illarionov B, Krisilia V, Pessanha de Carvalho L, Lungerich B, Sakamoto Y, Höfmann S, Bacher A, Kalscheuer R, Held J, Fischer M, Tanaka N, Kurz T.   +13 more
europepmc   +3 more sources

A Chemical Probe for Increasing Leaf Tocopherol Levels by Coordinated Modulation of Biosynthesis, Competition and Storage. [PDF]

Plant Biotechnol J
ABSTRACT Plant biofortification with phytonutrients typically relies on metabolic engineering strategies known as ‘push’ (enhancing biosynthetic flux), ‘block’ (inhibiting competing pathways) and ‘pull’ (promoting metabolite storage). Here, we describe a novel synthetic compound, X57, that simultaneously targets biosynthesis, competition and storage to
Perez-Colao P, Glauser G, Cruces J, Lozano-Juste J, Rodriguez-Concepcion M.   +4 more
europepmc   +2 more sources

Preparation of gem-difluorinated retrohydroxamic-fosmidomycin [PDF]

ARKIVOC, 2015
From several decades, some organophosphorus compounds specifically designed to alter biological systems were introduced on market as agr ochemicals (ie glyphosate and glufosinate as herbicides). Nevertheless, it becomes necessary to find new compounds in order to counter plant resistances already observed with glyphosate. Fosmi domicyn and its N-acetyl
Jean-Noël Volle, Camille Midriera, Vincent Blanchard, Ralf Braun, Klaus Haaf, Lothar Willms, Jean-Luc Pirata, David Virieux   +7 more
doaj   +2 more sources

Sub-inhibitory fosmidomycin exposures elicits oxidative stress in Salmonella enterica serovar Typhimurium LT2. [PDF]

PLoS ONE, 2014
Fosmidomycin is a time-dependent nanomolar inhibitor of methylerythritol phosphate (MEP) synthase, which is the enzyme that catalyzes the first committed step in the MEP pathway to isoprenoids.
David T Fox, Emily N Schmidt, Hongzhao Tian, Suraj Dhungana, Michael C Valentine, Nicole V Warrington, Paul D Phillips, Kellan B Finney, Emily K Cope, Jeff G Leid, Charles A Testa, Andrew T Koppisch   +11 more
doaj   +1 more source